Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Acquisition expands Merck’s growing hematology portfolio
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
The CRL did not identify any outstanding scientific issues with the product.
CGHS would give robust coverage to pensioners and with new innovations and practices
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Subscribe To Our Newsletter & Stay Updated
